The world's first freeze-dried mRNA vaccine preclinical data release How is the progress of mRNA vaccine at home and abroad?

A few days ago, the preclinical research data of the lyophilized mRNA COVID-19 vaccine of Ruikeji Bio, a subsidiary of Ruike Bio, was published in the biological preprint journal BioRxiv

It is reported that the freeze-dried mRNA-LNP new coronary pneumonia vaccine adopts the LNP delivery system, and the self-developed freeze-drying technology is used to achieve formulation stability at 4°C and 25°C

Previous studies have shown that the process of dehydration and lyophilization causes mechanical stress that can easily disrupt the structure of mRNA

Likewise, the lyophilization process does not affect the biological activity and immunogenicity of the mRNA vaccine

mRNA vaccines belong to nucleic acid vaccines, which are designed to deliver mRNA of virus-related sequences synthesized in vitro into human cells to form immunity

Global marketed mRNA vaccines: Comirnaty and Spikevax

At present, two mRNA vaccines have been launched in the world: Pfizer/BioNtech's Comirnaty and Moderna's Spikevax

Although the mRNA vaccine has extremely strict storage and transportation temperature conditions, this has not stopped the vaccine from flourishing during the epidemic

According to the 221-year financial report released by Pfizer earlier, the total revenue of the new crown vaccine Comirnaty reached 36.

This shows how far-sighted Pfizer was in firmly choosing the mRNA vaccine technology route in the early days of the outbreak

mRNA strategic roadmap

Four latest agreements to advance mRNA strategy

Looking at Moderna, the company's official website shows that its 2021 performance report will be released on the 24th of this month

Domestic mRNA new crown vaccine: Fosun lincese-in, Watson lead self-developed

The domestic choice for the mRNA technology route is firstly the cooperation between Fosun Pharma and BioNTech

In March 2020, Fosun Pharma took the lead and won the exclusive rights to R&D and commercialization of BioNTech in Greater China

In 2021, while Pfizer/BioNTech's mRNA new crown vaccine is making a big splash in the global war against the epidemic, Fubitai® has successively obtained approvals in Hong Kong and Macau, China, and emergency use authorization in Taiwan, China

In July 2021, Fosun Pharma stated that the NMPA's approval of Fubitai® has been basically completed, and it is expected to become the first mRNA new crown vaccine in China

In August 2021, the first transcript of Forbitx Greater China was released

In terms of independent research and development of domestic mRNA new crown vaccines, the ARCoV vaccine of Watson/Aibo, which was the first to enter the international phase III clinical trials, is undoubtedly in the "first echelon" of China's mRNA new crown vaccines

It is reported that Aibo's mRNA vaccine can be stored below 2℃~8℃ for at least 6 months.
Although it is not as good as the storage and transportation conditions of freeze-dried mRNA vaccine, it still greatly reduces the challenges brought by cold chain transportation
.

Watson Bio has already deployed an mRNA vaccine production line in Yuxi, Yunnan Province as early as December 2020, with a total investment of 280 million yuan and an estimated production capacity of 200 million doses per year
.
Against the background of the global shortage of new crown vaccine supply, if the vaccine can be successfully launched, it may bring billions of profits to Watson Bio
.

Reference sources: Medical Notes, MedTrend Medical Trends, Sina Pharmaceutical News, Xinkangjie